Immunohistochemical analysis of human tumor samples revealed MerTK expression in a large fraction (>50%) of breast cancer, melanoma and non-small cell lung cancers….In in vivo xenograft models we demonstrate that RGX-019 suppressed tumor progression by >70%. Anti-tumor activity was associated with near complete depletion of MerTK from the surface of cancer cells in vivo.